Physician profile
Kayla Roller
NPI 1174291512
$2,940.96
in general payments reported to CMS, 2019-2025
22 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $427 · 2023: $1,057 · 2024: $582 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,374.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $789.56 | 2022-2025 | |
| Amgen INC. | $319.90 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $318.19 | 2022-2025 | |
| Penumbra, INC. | $305.84 | 2025 | Indigo System, Penumbra System |
| Astrazeneca Pharmaceuticals Lp | $168.38 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.12 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $145.14 | 2025 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $115.78 | 2022-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $78.51 | 2023-2025 | Eliquis, Camzyos |
| Regeneron Healthcare Solutions, INC. | $71.18 | 2022-2023 | Evkeeza |
| Merck Sharp & Dohme LLC | $60.78 | 2022-2024 | Verquvo |
| Novo Nordisk INC | $57.64 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $49.76 | 2024-2025 | |
| Esperion Therapeutics, INC. | $46.77 | 2024 | Nexletol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $31.17 | 2022-2023 | Arcalyst |
| Irhythm Technologies, INC. | $27.08 | 2023 | Zio Xt Patch |
| Edwards Lifesciences Corporation | $22.31 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Daiichi Sankyo INC. | $17.88 | 2025 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $16.71 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $16.43 | 2024 | Arcalyst |
| Chiesi USA, INC. | $16.05 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Roller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.